Mitoxantrone as a potential therapy for primary progressive multiple sclerosis

No abstract is available for this paper.

• Publication year

  2004

• Venue

  Multiple Sclerosis

• Publication date

  2004-05-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1191/1352458504ms1032oaPMID 15218811
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Pharmacology of mitoxantrone: mode of action and pharmacokinetics

  2004cited by this paper
• Clinical parameters and intrathecal IgG synthesis as prognostic features in multiple sclerosis. Part I

  2004cited by this paper
• A study of therapy-related acute leukaemia after mitoxantrone therapy for multiple sclerosis

  2002cited by this paper
• Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial.

  2002cited by this paper
• Inhibition of Basal and Transforming Growth Factor-β-induced Stimulation of COL1A1 Transcription by the DNA Intercalators, Mitoxantrone and WP631, in Cultured Human Dermal Fibroblasts*

  2002cited by this paper
• Cardiac adverse effects associated with mitoxantrone (Novantrone) therapy in patients with MS

  2002cited by this paper
• European/Canadian multicenter, double‐blind, randomized, placebo‐controlled study of the effects of glatiramer acetate on magnetic resonance imaging–measured disease activity and burden in patients with relapsing multiple sclerosis

  2001cited by this paper
• PRISMS-4: Long-term efficacy of interferon-&bgr;-1a in relapsing MS

  2001cited by this paper
• Glatiramer acetate (Copaxone) treatment in relapsing–remitting MS

  2000cited by this paper
• Sustained clinical benefits of glatiramer acetate in relapsing multiple sclerosis patients observed for 6 years

  2000cited by this paper
• Efficacy of donepezil in Alzheimer ’ s disease : Fact or artifact ?

  1999cited by this paper
• The natural history of multiple sclerosis: a geographically based study. 5. The clinical features and natural history of primary progressive multiple sclerosis.

  1999cited by this paper
• Multiple sclerosis that is progressive from the time of onset: clinical characteristics and progression of disability.

  1999cited by this paper
• A comparison of DNA-binding drugs as inhibitors of E2F1- and Sp1-DNA complexes and associated gene expression.

  1998cited by this paper
• Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability

  1998cited by this paper
• Mitoxantrone. A review of its pharmacology and clinical efficacy in the management of hormone-resistant advanced prostate cancer.

  1997cited by this paper
• Therapeutic effect of mitoxantrone combined with methylprednisolone in multiple sclerosis: a randomised multicentre study of active disease using MRI and clinical criteria.

  1997cited by this paper
• Mitoxantrone immunotherapy in multiple sclerosis

  1996cited by this paper
• Defining the clinical course of multiple sclerosis

  1996cited by this paper
• Intramuscular interferon beta‐1a for disease progression in relapsing multiple sclerosis

  1996cited by this paper
• Alterations in the topoisomerase II alpha gene, messenger RNA, and subcellular protein distribution as well as reduced expression of the DNA topoisomerase II beta enzyme in a mitoxantrone-resistant HL-60 human leukemia cell line.

  1995cited by this paper
• Copolymer 1 reduces relapse rate and improves disability in relapsing‐remitting multiple sclerosis

  1995cited by this paper
• Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group.

  1995cited by this paper
• Alterations in the Topoisomerase IIα Gene, Messenger RNA, and Subcellular Protein Distribution as well as Reduced Expression of the DNA Topoisomerase IIβ Enzyme in a Mitoxantrone-resistant HL-60 Human Leukemia Cell Line

  1995cited by this paper
• Interferon beta‐1b is effective in relapsing‐remitting multiple sclerosis

  1993cited by this paper
• Interferon beta‐1b is effective in relapsing‐remitting multiple sclerosis

  1993cited by this paper
• Are alkylating agents a necessary component in the therapy of Hodgkin's disease.

  1993cited by this paper
• Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group.

  1993cited by this paper
• The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disability.

  1989cited by this paper
• Course and prognosis of chronic progressive multiple sclerosis: Results of an epidemiological study

  1988cited by this paper
• Selective immunomodulation by the antineoplastic agent mitoxantrone. I. Suppression of B lymphocyte function.

  1986cited by this paper
• Selective immunomodulation by the antineoplastic agent mitoxantrone. II. Nonspecific adherent suppressor cells derived from mitoxantrone-treated mice.

  1986cited by this paper
• Inhibition of the induction of alloreactivity with mitoxantrone.

  1986cited by this paper
• Clinical pharmacology of mitoxantrone.

  1986cited by this paper
• Molecular and biochemical pharmacology of mitoxantrone.

  1983cited by this paper
• Pharmacology of mitoxantrone in cancer patients

  1982cited by this paper
• Course and prognosis of multiple sclerosis assessed by the computerized data processing of 349 patients.

  1980cited by this paper

• Investigation of miR-146a expression profiles in fecal samples of patients with multiple sclerosis for early diagnosis and treatment

  2023cites this paper
• Bruton’s tyrosine kinase as a promising therapeutic target for multiple sclerosis

  2023cites this paper
• Bruton’s Tyrosine Kinase Inhibitors in Multiple Sclerosis: Pioneering the Path Towards Treatment of Progression?

  2022cites this paper
• Central nervous system macrophages in progressive multiple sclerosis: relationship to neurodegeneration and therapeutics

  2022cites this paper
• Host-Guest Complexation of Cucurbit[7]Uril and Cucurbit[8]Uril with the Antineoplastic and Multiple Sclerosis Agent Mitoxantrone (Novantrone).

  2021cites this paper
• Treatment for patients with primary progressive multiple sclerosis

  2019cites this paper
• Efficacy and safety of mycophenolate mofetil in progressive multiple sclerosis patients

  2018cites this paper
• Efficacy and safety of mitoxantrone use in primary and secondary progressive multiple sclerosis – study site experience based on the therapy of 104 patients

  2017cites this paper
• Effects of dimethyl fumarate in two animal models of MS

  2017cites this paper
• Lack of efficacy of mitoxantrone in primary progressive Multiple Sclerosis irrespective of pharmacogenetic factors: a multi-center, retrospective analysis.

  2015cites this paper
• Spectroscopic studies of the effects of anticancer drug mitoxantrone interaction with calf-thymus DNA.

  2013cites this paper
• Current theories for multiple sclerosis pathogenesis and treatment

  2012cites this paper
• 11 – Sclérose en plaques

  2012cites this paper
• Non-myeloablative Autologous Haematopoietic Stem Cell Transplantation with Consolidation Therapy using Mitoxantrone as a Treatment Option in Multiple Sclerosis Patients

  2011cites this paper
• Rational drug discovery : structural studies of protein-ligand complexes

  2011cites this paper
• Chronic Progressive Multiple Sclerosis – Pathogenesis of Neurodegeneration and Therapeutic Strategies

  2010cites this paper
• Understanding progression in primary progressive multiple sclerosis: a longitudinal clinical and magneticresonance imaging study

  2010cites this paper
• Lesion enhancement diminishes with time in primary progressive multiple sclerosis

  2010cites this paper
• PRIMARY PROGRESSIVE MULTIPLE SCLEROSIS

  2010cites this paper
• ABC-transporter gene-polymorphisms are potential pharmacogenetic markers for mitoxantrone response in multiple sclerosis.

  2009cites this paper
• Multiple Sclerosis and Demyelinating Diseases

  2007cites this paper
• Immunological studies of mitoxantrone in primary progressive MS.

  2006cites this paper
• Therapeutic role of mitoxantrone in multiple sclerosis.

  2006cites this paper
• Current trials in multiple sclerosis: established evidence and future hopes

  2005cites this paper